Thus, MSC-Exos are for a less risky disease therapy than hUMSC-based therapeutic agents, and they have a wider range of therapeutic applications.[8] Our previous research showed that miR-218-5p suppresses EGFR expression in pterygium tissues and human pterygium epithelial cells through the PI3K/Akt/mTOR signaling pathway.[9] At present, we investigated the inhibitory effect of MSC-Exos on oxidative stress in HRECs induced by VEGF-165 and the molecular mechanism. The gene discussed is EGFR; the disease is pterygium.